TSXV - Free Realtime Quote CAD

Thiogenesis Therapeutics, Corp. (TTI.V)

0.6400
0.0000
(0.00%)
As of May 8 at 1:25:34 PM EDT. Market Open.
Currency in CAD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
2/28/2022
Total Revenue
0
0
0
0
0
Operating Expense
3,579.2740
3,579.2740
5,206.0210
1,974.8470
224.6780
Operating Income
-3,579.2740
-3,579.2740
-5,206.0210
-1,974.8470
-224.6780
Net Non Operating Interest Income Expense
200.3270
200.3270
171.1650
2.0580
0.2210
Other Income Expense
233.2170
233.2170
-28.1550
-1,951.4620
--
Pretax Income
-3,145.7300
-3,145.7300
-5,063.0110
-3,924.2510
-224.4570
Net Income Common Stockholders
-3,145.7300
-3,145.7300
-5,063.0110
-3,924.2510
-224.4570
Diluted NI Available to Com Stockholders
-3,145.7300
-3,145.7300
-5,063.0110
-3,924.2510
-224.4570
Basic EPS
-0.07
--
-0.13
-0.16
-0.01
Diluted EPS
-0.07
--
-0.13
-0.16
-0.01
Basic Average Shares
45,360.6520
--
39,129.3340
25,291.5540
27,910.1750
Diluted Average Shares
45,360.6520
--
39,129.3340
25,291.5540
27,910.1750
Total Expenses
3,579.2740
3,579.2740
5,206.0210
1,974.8470
224.6780
Net Income from Continuing & Discontinued Operation
-3,145.7300
-3,145.7300
-5,063.0110
-3,924.2510
-224.4570
Normalized Income
-3,378.9470
-3,378.9470
-5,034.8560
-3,980.4420
-224.4570
Interest Income
200.3270
200.3270
171.1650
6.1810
0.2470
Interest Expense
--
--
0
4.1230
0.0260
Net Interest Income
200.3270
200.3270
171.1650
2.0580
0.2210
EBIT
-3,579.2740
-3,579.2740
-5,206.0210
-3,920.1280
-224.4310
EBITDA
-3,579.2740
-3,579.2740
-5,206.0210
-3,920.1280
-224.4310
Net Income from Continuing Operation Net Minority Interest
-3,145.7300
-3,145.7300
-5,063.0110
-3,924.2510
-224.4570
Total Unusual Items Excluding Goodwill
233.2170
233.2170
-28.1550
56.1910
--
Total Unusual Items
233.2170
233.2170
-28.1550
56.1910
--
Normalized EBITDA
-3,812.4910
-3,812.4910
-5,177.8660
-3,976.3190
-224.4310
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
2/28/2022 - 4/13/2022

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BETR.CN BetterLife Pharma Inc.
0.0850
-10.53%
 
TCRX TScan Therapeutics, Inc.
1.3450
-2.55%
 
NGEN.V NervGen Pharma Corp.
3.5300
-1.67%
 
SVA.TO Sernova Biotherapeutics Inc
0.1950
-2.50%
 
DBVT DBV Technologies S.A.
9.99
+1.53%
 
TIL Instil Bio, Inc.
13.16
+1.00%
 
OMER Omeros Corporation
6.26
-0.87%
 
GALT Galectin Therapeutics Inc.
1.3450
-3.93%
 
MCRB Seres Therapeutics, Inc.
7.09
+1.94%
 
AUPH Aurinia Pharmaceuticals Inc.
7.97
-1.79%